1. Amoxicillin Trihydrate
2. Pharmacological Class: Aminopenicillin Beta-Lactam Antibiotic (Bactericidal Cell-Wall Peptidoglycan Synthesis Inhibitor; WHO 'Access' Group) • 3. Therapeutic Category: Antimicrobials ā Antibacterial & Antibiotic Agents (Ch 08)
4. Clinical Overview & Verified Formulation Identity
Amoxicillin Trihydrate
Code: [8.1] | Stable ID: TIP-MED-000129
Mox (Sun Pharma), Novamox (Cipla), Almox (Alkem)
Oral Capsules / Dispersible Tablets: 250 mg, 500 mg; Paediatric Dry Syrup for Reconstitution: 125 mg/5 mL, 250 mg/5 mL; Drops: 100 mg/mL
Route: Oral / Parenteral / Topical as specified by formulation
Schedule H (Drugs Rules, 1945 ā Prescription Only)
True
5 & 6. Mechanism of Action & Pharmacodynamics
Bactericidal time-dependent beta-lactam antibiotic (`fT > MIC`) that binds to bacterial Penicillin-Binding Proteins (PBPs 1A, 2, 3), inhibiting transpeptidation of peptidoglycan cell-wall cross-links and triggering autolysin-mediated bacterial cell lysis.
8. Therapeutic Indications
- Community-acquired respiratory tract infections (acute otitis media, bacterial pharyngotonsillitis, sinusitis, community-acquired pneumonia)
- Helicobacter pylori eradication regimens (in combination with Clarithromycin/Metronidazole and a PPI) and dental abscesses
10. Dosage and Administration (Educational Reference Summary)
Administration & Timing: May be taken with or without food (taking at the start of a light meal improves GI tolerability, particularly when combined with Clavulanic Acid). Space doses evenly every 8 hours (`fT > MIC` time-dependent killing).
11 & 13. Contraindications, Precautions and Warnings
- History of immediate IgE-mediated hypersensitivity (anaphylaxis, angioedema, bronchospasm, Stevens-Johnson syndrome) to Penicillins or any Beta-Lactam antibiotic
- Avoid in suspected infectious mononucleosis (Epstein-Barr virus) due to >70% incidence of generalised maculopapular morbilliform rash
No routine hepatic dose adjustment required for plain Amoxicillin (monitor LFTs if co-formulated with Clavulanate, which carries cholestatic jaundice risk).
7, 12, 14ā18. Detailed Pharmacokinetics, Interactions, Special Populations & Counselling
7 & 16. Pharmacokinetics (ADME) & Renal / Hepatic Considerations
7. Pharmacokinetics (Absorption, Distribution, Metabolism, Excretion): Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
16a. Renal Considerations: Excreted primarily unchanged via glomerular filtration and tubular secretion: CrCl 10ā30 mL/min: 250ā500 mg every 12 hours; CrCl < 10 mL/min: 250ā500 mg every 24 hours; administer dose after haemodialysis session.
16b. Hepatic Considerations: No routine hepatic dose adjustment required for plain Amoxicillin (monitor LFTs if co-formulated with Clavulanate, which carries cholestatic jaundice risk).
12 & 14. Adverse Effects & Drug Interactions
- Hypersensitivity reactions ranging from delayed maculopapular rash to immediate IgE-mediated urticaria and anaphylaxis
- Diarrhoea, nausea, candidal superinfection (oral/vulvovaginal thrush), rare Clostridioides difficile colitis
- Methotrexate: Penicillins compete for renal organic anion tubular secretion (OAT1/OAT3), reducing Methotrexate clearance and risking severe myelosuppression.
- Allopurinol: Co-administration significantly increases the incidence of non-allergic maculopapular skin rash.
- Warfarin / Oral Anticoagulants: Alteration of gut flora may potentiate INR elevation; monitor INR during systemic antibiotic therapy.
15, 17 & 18. Special Populations, Clinical Monitoring & Patient Counselling
15. Use in Special Populations (Pregnancy, Lactation, Paediatrics, Geriatrics): Evaluate maternal-foetal benefit-risk ratio, paediatric mg/kg ceiling, and geriatric renal function prior to prescribing.
17. Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
18. Patient Counselling & Storage:- Always confirm absence of Penicillin allergy before dispensing the first dose.
- Complete the full prescribed antibiotic course at evenly spaced intervals (every 8 hours for TID) even if fever subsides after 48 hours.
- For paediatric dry syrup powder: reconstitute to the ring mark with boiled and cooled water, shake well before each dose, and discard unused suspension after 7ā10 days (per manufacturer label).
Storage & Dispensing Notes: Store capsules below 25°C in a dry place; reconstituted oral suspensions should be stored in a cool place / refrigerator (2°Cā8°C) and discarded after 7ā14 days.
Visual Pharmacology Illustration (PLATE-8.9)
19. Authoritative References & Source Traceability
Primary Reference Record: Indian Pharmacist Desk Reference ā Professional Edition 2.7 (2026ā27) by Tejas Nartam; ICMR Antimicrobial Treatment Guidelines; NFI 7th Ed (2026).
Verification Portals: Indian Pharmacopoeia Commission (IPC) • CDSCO (India Jurisdiction) • NCBI Bookshelf • DailyMed (US FDA Label Reference)
Last Reviewed Date: 2026-11-08 • Related Study Guide: Antimicrobial Stewardship & PK/PD Optimization →